Pacgen to Exhibit at the AMP 2012 Annual Meeting in Long Beach, California

Pacgen Life Science Corporation ("Pacgen") (TSX VENTURE:PBS) announced today
that it will host an exhibit at the Annual Meeting of Association for Molecular
Pathology (the "AMP 2012 Annual Meeting"). The AMP 2012 Annual Meeting will be
held at the Long Beach Convention & Entertainment Center from October 25-27,
2012. Pacgen will co-host with its manufacturing partner, General Biologicals
Corporation, at booth no 630 to introduce its lab instruments (FIT-X1), reagent
kits, and a new product launch, BioFibroScore. 


About Pacgen

Pacgen is a life science technology company focused on the commercialization of
biomedical products and services, including its previous development of novel
therapeutic drug candidates. The Company is currently looking to facilitate its
corporate transformation from a bio-pharma R&D business into a
revenue-generating company. For additional information, please visit
www.pacgenlife.com.


Forward looking Statements

Certain statements included in this press release may be considered
forward-looking. Statements relating to, among other things, anticipated
financial performance, business prospects, strategies, regulatory developments,
market acceptance and future commitments constitute forward-looking statements.
All forward-looking statements are based on Pacgen's current beliefs and
expectations as well as assumptions relating to the successful completion of its
clinical trials and pre-clinical studies, the time and process required to
obtain regulatory approval for commercialization of its product, the ability of
Pacgen to raise additional capital in future on favourable terms, the impact of
competitive products and pricing in the market, new product development, and the
successful and timely completion of corporate collaborations or licensing
arrangements for its research programs. Such statements involve known and
unknown risks, uncertainties and other factors that may cause actual results,
level of activity, performance or achievements to be materially different from
those implied by such statements, and therefore these statements should not be
read as guarantees of future performance or results. Such factors include, among
others, our stage of development, lack of product revenues, additional capital
requirements, risk associated with completion of clinical trials and obtaining
regulatory approval, dependence on collaborative partners, and our ability to
protect our intellectual property. 


Wherever possible, words such as "anticipate", "believe", "expect", "may",
"could", "will", "potential", "intend", "estimate", "should", "plan", "predict",
"project" or the negative or other variations of such expressions reflect
Pacgen's current beliefs and assumptions and are based on the information
currently available to Pacgen. Certain risks and uncertainties, including those
risk factors identified by Pacgen in its annual management's discussion and
analysis dated July 29, 2011 and annual information form dated July 31, 2008,
may cause our actual results, level of activity, performance or achievements to
differ materially from those implied by forward looking statements. Readers are
cautioned not to place undue reliance on these forward-looking statements, which
are made only as of the date of this press release. Pacgen disclaims any
intention or obligation to update or revise any forward-looking statements,
whether as a result of new information, future events or otherwise, except as
required by law. For all forward-looking statements, Pacgen claims the safe
harbour for forward-looking statements within the meaning of the Private
Securities Litigation Reform Act of 1995. 


FOR FURTHER INFORMATION PLEASE CONTACT: 
Pacgen Life Science Corporation
Ming S. Liu
Chief Executive Officer
714-686-2577
[e-mail]
www.pacgenlife.com